Skip to content
DataLookout
Menu

NCT02877303

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

StatusRecruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved 2 years later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 50 versions: 19 with changes below, 31 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Nov 1, 2026 to Nov 1, 2028
    • Eligibility criteria expanded, about 15 words
    • Publications: details revised at 4 of 4 entries
  2. Notable Trial status: Active, Not Recruiting to Recruiting
    • Site details revised
    v43
  3. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v42
  4. Notable Primary and study completion dates: Nov 1, 2023 to Nov 1, 2026v35
  5. Notable Eligibility criteria shortened, about 7 wordsv29
Show 13 earlier versionsHide 13 earlier versions
  1. Notable Primary and study completion dates: Nov 1, 2021 to Nov 1, 2023v26
  2. Minor Enrollment target: 60 to 80v24 Show 4 more changesShow less
    • Interventions: Blinatumomab (Biological), Cyclophosphamide (Drug), Cytarabine (Drug), Dexamethasone (Drug), Doxorubicin Hydrochloride (Drug), Laboratory… to Blinatumomab (Biological), Cyclophosphamide (Drug), Cytarabine (Drug), Dexamethasone (Drug), Doxorubicin Hydrochloride (Drug), Inotuzumab…
    • Study description expanded, about 30 words
    • Site contact updated
    • Study title expanded, about 2 words
  3. Notable Primary and study completion dates: Nov 1, 2020 to Nov 1, 2021v22
  4. Notable Primary endpoint revisedv18 Show 9 more changesShow less
    • Eligibility criteria expanded, about 2 words
    • Primary completion date: Nov 2020 to Nov 1, 2020
    • Study completion date: Nov 2021 to Nov 1, 2020
    • Interventions: 6-Mercaptopurine (Drug), Blinatumomab (Drug), Cyclophosphamide (Drug), Cytarabine (Drug), Dexamethasone (Drug), Doxorubicin (Drug), G-CSF… to Blinatumomab (Biological), Cyclophosphamide (Drug), Cytarabine (Drug), Dexamethasone (Drug), Doxorubicin Hydrochloride (Drug), Laboratory…
    • Secondary endpoints expanded, about 14 words
    • Study description expanded, about 427 words
    • Study site revised
    • Collaborator revised
    • Study title shortened, about 3 words
  5. Minor Study completion date: Nov 2020 to Nov 2021v17
  6. Minor Study description shortened, about 1,411 wordsv15
  7. Notable Trial status: Active, Not Recruiting to Recruiting
    • Enrollment target: 20 to 60
    • Study description revised
    • Site details revised
    v12
  8. Notable Eligibility criteria shortened, about 56 words
    • Study description expanded, about 169 words
    v11
  9. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 60 to confirmed 20
    • Start date: Nov 2016 to Nov 1, 2016
    • Site details revised
    v9
  10. Notable Eligibility criteria expanded, about 120 words
    • Study description expanded, about 51 words
    v7
  11. Minor Study completion date: Nov 2020
    • Study description expanded, about 137 words
    v5
  12. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study description shortened, about 66 words
    • Site details revised
    v4
  13. Notable Eligibility criteria expanded, about 48 words
    • Study description shortened, about 7 words
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Relapse-free survival (RFS)
Timeframe: From date of treatment start until the date of death or disease relapse, assessed for up to 24 months

Secondary (4)

Overall survival
Overall response rate
Minimal residual disease negativity rate
Incidence of adverse events

Arms and interventions

Treatment (blinatumomab, inotuzumab, combination chemotherapy)Experimental

See detailed description.

Biologicals: Blinatumomab, Inotuzumab Ozogamicin, Ofatumumab, Rituximab

Drugs: Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Mercaptopurine, Methotrexate, Prednisone, Vincristine Sulfate

Other: Laboratory Biomarker Analysis

Sites

1 site in 1 country

  • M D Anderson Cancer CenterHouston, Texas, United States